[go: up one dir, main page]

HUT77006A - Új kinuklidinszármazékok és ezeket tartalmazó gyógyászati készítmények - Google Patents

Új kinuklidinszármazékok és ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUT77006A
HUT77006A HU9701895A HU9701895A HUT77006A HU T77006 A HUT77006 A HU T77006A HU 9701895 A HU9701895 A HU 9701895A HU 9701895 A HU9701895 A HU 9701895A HU T77006 A HUT77006 A HU T77006A
Authority
HU
Hungary
Prior art keywords
quinuclidine derivatives
medicinal composition
diseases
novel quinuclidine
novel
Prior art date
Application number
HU9701895A
Other languages
English (en)
Other versions
HU223778B1 (hu
Inventor
Masahiko Hayakawa
Ken Ikeda
Yasuo Isomura
Ryo Naito
Yoshinori Okamoto
Makoto Takeuchi
Yasuhiro Yonetoku
Original Assignee
Yamanouchi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUT77006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co., Ltd. filed Critical Yamanouchi Pharmaceutical Co., Ltd.
Publication of HUT77006A publication Critical patent/HUT77006A/hu
Publication of HU223778B1 publication Critical patent/HU223778B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Tea And Coffee (AREA)
HU9701895A 1994-12-28 1995-12-27 Új kinuklidinszármazékok és ezeket tartalmazó gyógyászati készítmények HU223778B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
PCT/JP1995/002713 WO1996020194A1 (fr) 1994-12-28 1995-12-27 Nouveaux derives de quinuclidine et composition pharmaceutique les contenant

Publications (2)

Publication Number Publication Date
HUT77006A true HUT77006A (hu) 1998-03-02
HU223778B1 HU223778B1 (hu) 2005-01-28

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9701895A HU223778B1 (hu) 1994-12-28 1995-12-27 Új kinuklidinszármazékok és ezeket tartalmazó gyógyászati készítmények

Country Status (24)

Country Link
US (2) US6017927A (hu)
EP (1) EP0801067B1 (hu)
JP (1) JP3014457B2 (hu)
KR (1) KR100386487B1 (hu)
CN (1) CN1045601C (hu)
AT (1) ATE233761T1 (hu)
AU (1) AU695616B2 (hu)
CA (1) CA2208839C (hu)
DE (2) DE69529844T2 (hu)
DK (1) DK0801067T3 (hu)
ES (1) ES2193208T3 (hu)
FI (1) FI115631B (hu)
FR (1) FR04C0032I2 (hu)
HU (1) HU223778B1 (hu)
LU (1) LU91133I9 (hu)
MX (1) MX9704880A (hu)
NL (1) NL300141I1 (hu)
NO (4) NO2005012I1 (hu)
NZ (1) NZ298144A (hu)
PL (1) PL182344B1 (hu)
PT (1) PT801067E (hu)
RU (1) RU2143432C1 (hu)
TW (1) TW305842B (hu)
WO (1) WO1996020194A1 (hu)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128028A2 (en) * 2007-04-11 2008-10-23 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
DK1300407T4 (da) * 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamater afledt af arylalkylaminer
AU2002228015B2 (en) * 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
EP1353919B1 (en) 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same
ES2359719T3 (es) * 2001-07-10 2011-05-26 Astellas Pharma Inc. Composición farmacéutica comprendiendo quinuclidin-3'-il 1-fenil-1,2,3,4-tetrahidroisoquinolin-2-carboxilato para el tratamiento de la cistitis instersticial y/o la prostatitis no bacteriana.
IL162596A0 (en) * 2001-12-20 2005-11-20 S A L V A T Lab Sa 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists
JP4466370B2 (ja) * 2002-06-07 2010-05-26 アステラス製薬株式会社 過活動膀胱治療剤
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
ATE419236T1 (de) 2002-07-08 2009-01-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten
WO2004014853A1 (en) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1545508A4 (en) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
JP2006501236A (ja) 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体
MXPA05003398A (es) * 2002-10-29 2005-06-22 Pharmacia & Upjohn Co Llc Compuestos de amonio cuaternario.
ATE400553T1 (de) 2002-12-10 2008-07-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors
EP1480631B1 (en) * 2002-12-20 2007-08-01 Dynogen Pharmaceuticals Inc. Methods of treating non-painful bladder disorders using alpha2-delta- subunit calcium channel modulators
US7501443B2 (en) 2002-12-23 2009-03-10 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
EP1583741A1 (en) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004084879A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615887A1 (en) 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP2006514978A (ja) 2003-04-10 2006-05-18 ランバクシー ラボラトリーズ リミテッド ムスカリン受容体アンタゴニストである置換アザビシクロヘキサン誘導体
EA009387B1 (ru) 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
US20080287680A1 (en) * 2004-02-09 2008-11-20 Astellas Pharma Inc. Solifenacin Succinate-Containing Composition
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
CA2560080A1 (en) * 2004-03-16 2005-09-22 Astellas Pharma Inc. Solifenacin-containing composition
JPWO2005087231A1 (ja) 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
KR101836467B1 (ko) * 2004-03-25 2018-03-08 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
CN1934109B (zh) * 2004-03-25 2010-06-23 安斯泰来制药株式会社 用于固体制剂的索非那新或其盐的组合物
WO2006035280A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP4636445B2 (ja) * 2004-12-27 2011-02-23 アステラス製薬株式会社 ソリフェナシンまたはその塩の安定な粒子状医薬組成物
WO2006070735A1 (ja) * 2004-12-27 2006-07-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の安定な粒子状医薬組成物
CA2599158C (en) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
EP1904495A2 (en) * 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
BRPI0617674A2 (pt) 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
CA2630846A1 (en) * 2005-12-21 2007-07-05 Teva Pharmaceutical Industries Ltd. Intermediates for preparing solifenacin
CZ300699B6 (cs) * 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
US20090326230A1 (en) * 2006-07-19 2009-12-31 Dr. Reddy's Laboratories Ltd. Process for preparing solifenacin and its salts
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2043639A2 (en) * 2006-07-24 2009-04-08 Teva Pharmaceutical Industries Ltd. Processes for preparing polymorphic forms of solifenacin succinate
US20080091023A1 (en) * 2006-08-03 2008-04-17 Nurit Perlman Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EP2102200A2 (en) * 2006-11-22 2009-09-23 Medichem, S.A. An improved process for the synthesis of solifenacin
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
AR066206A1 (es) * 2007-03-30 2009-08-05 Medichem Sa Proceso para la sintesis de solifenacina
US20090099365A1 (en) * 2007-07-13 2009-04-16 Nurit Perlman Processes for solifenacin preparation
JPWO2009013846A1 (ja) * 2007-07-20 2010-10-07 アステラス製薬株式会社 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
CA2704298C (en) 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
WO2009073203A1 (en) * 2007-12-04 2009-06-11 Amgen Inc. Trp-m8 receptor ligands and their use in treatments
EP2229387A1 (en) * 2007-12-04 2010-09-22 Cadila Healthcare Limited Process for preparing chemically and chirally pure solifenacin base and its salts
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8404701B2 (en) 2008-03-27 2013-03-26 Chase Pharmaceuticals Corporation Use and composition for treating dementia
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
SI3067353T1 (en) 2008-07-29 2018-03-30 Krka, D.D., Novo Mesto Process for the preparation of solifenacin salts and their inclusion in pharmaceutical dosage forms
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
NZ594311A (en) * 2009-02-04 2013-05-31 Astellas Pharma Inc Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
PL2406257T3 (pl) 2009-03-09 2020-01-31 Megafine Pharma (P) Ltd. Nowy sposób wytwarzania solifenacyny i jej nowy produkt pośredni
JP4816828B2 (ja) 2009-03-30 2011-11-16 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011048607A1 (en) 2009-09-25 2011-04-28 Cadila Healthcare Limited Processes for the preparation of solifenacin or a salt thereof
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
ES2604705T3 (es) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Agente preventivo y/o remedio para el síndrome mano-pie
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
BR112012029461A2 (pt) 2010-05-19 2017-03-01 Astellas Pharma Inc composição farmacêutica contendo solifenacina
US8772491B2 (en) 2010-06-28 2014-07-08 Aurobindo Pharma Ltd Process for the preparation of solifenacin succinate
SI2590973T1 (sl) 2010-07-05 2017-01-31 Crystal Pharma, S.A.U. Soli solifenacina
CA2817336A1 (en) 2010-11-11 2012-05-18 Hexal Ag Crystalline solifenacin succinate
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP3167885A1 (en) 2011-05-10 2017-05-17 TheraVida, Inc. Combinations of solifenacin and pilocarpine for the treatment of overactive bladder
US20140228575A1 (en) 2011-06-22 2014-08-14 Isochem Process for the Preparation of Solifenacin and Salts Thereof
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
WO2014005601A1 (en) 2012-07-02 2014-01-09 Pharmathen S.A. A process for the preparation of solifenacin or a salt thereof
EP2891493A4 (en) 2012-08-31 2016-05-18 Astellas Pharma Inc MEDICAL COMPOSITION ADMINISTERED ORALLY
AU2013312749B2 (en) 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
TW201427977A (zh) * 2012-12-06 2014-07-16 Chiesi Farma Spa 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體致效劑活性之化合物
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
RU2641285C2 (ru) * 2013-07-13 2018-01-17 Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд Соединения хинина, способ их получения и их медицинское применение
US20170065589A1 (en) 2014-05-06 2017-03-09 Anthony G. Visco Methods of treating or preventing preterm labor
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
TW201927783A (zh) 2017-12-12 2019-07-16 美商阿爾庫達醫療公司 顆粒體蛋白前體調節劑及其使用方法
AU2020290485A1 (en) 2019-06-12 2021-12-02 Arkuda Therapeutics Progranulin modulators and methods of using the same
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053451T3 (es) * 1986-01-07 1994-08-01 Beecham Group Plc Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
EP1424021B1 (en) * 2002-11-27 2006-09-13 Selmac S.r.l. Device for positioning and clamping shaped elements and machine equipped with this device

Also Published As

Publication number Publication date
TW305842B (hu) 1997-05-21
NO2017055I1 (no) 2017-11-06
NO2005016I1 (no) 2005-08-29
FR04C0032I2 (fr) 2005-10-21
RU2143432C1 (ru) 1999-12-27
DE122004000048I1 (de) 2005-04-21
AU4355396A (en) 1996-07-19
NO318026B1 (no) 2005-01-24
KR100386487B1 (ko) 2003-09-26
WO1996020194A1 (fr) 1996-07-04
DK0801067T3 (da) 2003-06-30
DE122004000048I2 (de) 2006-02-02
MX9704880A (es) 1997-10-31
JPH09508401A (ja) 1997-08-26
PL182344B1 (pl) 2001-12-31
NO973027L (no) 1997-08-28
KR987000303A (ko) 1998-03-30
NO973027D0 (no) 1997-06-27
EP0801067A1 (en) 1997-10-15
NO2017055I2 (no) 2017-11-06
ES2193208T3 (es) 2003-11-01
EP0801067B1 (en) 2003-03-05
LU91133I9 (en) 2018-08-01
AU695616B2 (en) 1998-08-20
EP0801067A4 (en) 1998-03-11
NZ298144A (en) 1998-04-27
ATE233761T1 (de) 2003-03-15
LU91133I2 (fr) 2005-03-29
CA2208839A1 (en) 1996-07-04
CN1045601C (zh) 1999-10-13
CA2208839C (en) 2006-01-31
US6017927A (en) 2000-01-25
DE69529844D1 (de) 2003-04-10
CN1171109A (zh) 1998-01-21
PT801067E (pt) 2003-07-31
PL321019A1 (en) 1997-11-24
FI972775A0 (fi) 1997-06-27
NL300141I2 (nl) 2004-04-01
JP3014457B2 (ja) 2000-02-28
FI972775A (fi) 1997-08-22
DE69529844T2 (de) 2004-03-04
NO2005012I1 (no) 2005-06-06
NL300141I1 (nl) 2004-04-01
FR04C0032I1 (hu) 2005-02-11
HU223778B1 (hu) 2005-01-28
US6174896B1 (en) 2001-01-16
NO2005016I2 (no) 2008-02-11
FI115631B (fi) 2005-06-15

Similar Documents

Publication Publication Date Title
EP0801067A4 (en) NOVEL QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
HUT55605A (en) Herbicide compositions containing diamino-triazine derivatives as active componentsand process for producing the active components
ATE109484T1 (de) Thienopyridin -derivative und diese enthaltende arzneimittel.
HUT59139A (en) Process for producing tricyclic compounds and antimicrobial pharmaceutical compositions comprising same
AU4872793A (en) New ellipticine compounds, a process for their preparation and pharmaceutical compositions containing them
TW218016B (hu)
NO910904L (no) Fremgangsmaate for fremstilling av en substituert aminforbindelse.
GR3017801T3 (en) Flavone derivatives.
TW275629B (hu)
HUT68015A (en) New compound leustroducsin h, its preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20041207

HPC4 Succession in title of patentee

Owner name: ASTELLAS PHARMA INC., JP

FG4S Grant of supplementary protection certificate

Free format text: PRODUCT NAME: SOLIFENACIN AND ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS; REG. NO/DATE: OGYI-T-10051/01, 10052/01 20050218; FIRST REG.: NL RVG29151, RVG29152 20031216

Spc suppl protection certif: S0500016

Filing date: 20050811

Expiry date: 20151227

Extension date: 20181215